RASSF2 and Its Role in Gastric Cancer
Author Information
Author(s): Endoh M, Tamura G, Honda T, Homma N, Terashima M, Nishizuka S, Motoyama T
Primary Institution: Yamagata University School of Medicine
Hypothesis
RASSF2 is silenced by hypermethylation in gastric cancer.
Conclusion
Hypermethylation of RASSF2 is frequent in gastric cancer and contributes to its silencing.
Supporting Evidence
- Hypermethylation of RASSF2 was detected in 70% of gastric cancer cell lines.
- In primary gastric cancers, RASSF2 methylation frequencies ranged from 29% to 79%.
- Hypermethylation was mostly cancer-specific near the transcription start site.
Takeaway
RASSF2 is a gene that helps prevent cancer, and when it gets covered up by a chemical change called hypermethylation, it can lead to stomach cancer.
Methodology
Methylation status was examined in gastric cancer cell lines and primary gastric cancers using methylation-specific PCR.
Limitations
The study did not find significant correlations between RASSF2 methylation and other clinicopathological factors.
Participant Demographics
Patients ranged in age from 43 to 89 years, with a mean age of 67.6 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website